Search

509 Result(s)
Sort by

founding-member-of-QUTAC

founding-member-of-QUTAC

Together, the members of this newly founded consortium want to explore industrial applications for quantum computing
The power of our people

The power of our people

Diversity & Inclusion is an integral part of Boehringer Ingelheim's identity.
Collaboration-with-OxfordBioTherapeutics

Collaboration-with-OxfordBioTherapeutics

Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Partnership-with-clicktherapeutics

Partnership-with-clicktherapeutics

Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia
biolabs-heidelberg

biolabs-heidelberg

Boehringer Ingelheim supports the launch of BioLabs first European Location in Heidelberg.
Partnership WHO Foundation mental health

Partnership WHO Foundation mental health

Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
survodutide top-line results MASH fibrosis

survodutide top-line results MASH fibrosis

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Spotlight on GPP

Spotlight on GPP

Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
Strategic-collaboration-with-EnaraBio

Strategic-collaboration-with-EnaraBio

Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
2019 performance

2019 performance

Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
opening-solids-launch-fabrik

opening-solids-launch-fabrik

Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.
EC_approval_nintedanib_ILD_PF

EC_approval_nintedanib_ILD_PF

European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF